1. Home
  2. Clinical Topics
  3. Cardio-Pulmonary
  4. FDA approves drug to reduce CV deaths in patients with diabetes
Cardio-PulmonaryClinical TopicsDrugs and DevicesWeb Exclusives

FDA approves drug to reduce CV deaths in patients with diabetes

Share

On Dec. 2, the Food and Drug Administration (FDA) approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular (CV) death in adult patients with type 2 diabetes mellitus and cardiovascular disease. Read more

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts